Isomorphic Labs raises $2.1bn Series B

According to Sifted, Isomorphic Labs has raised $2.1bn in a Series B financing led by Thrive Capital. Sifted reports the round included the UK's Sovereign AI Fund, Abu Dhabi's MGX, Alphabet venture arm GV and Singapore's Temasek. VentureBurn reports Alphabet participated alongside GV and CapitalG, and places Isomorphic's cumulative funding at approximately $2.6bn. Sifted notes the company previously raised $600m in May 2025.

Per Sifted, Isomorphic, spun out of Google DeepMind in 2021, builds its discovery platform on AlphaFold-derived technology to predict protein structures and model molecular interactions. VentureBurn describes the company's internal platform as an "Isomorphic AI Drug Design Engine" that aims to extend structure prediction toward end-to-end drug design and candidate optimization.

Editorial analysis: Large, cross-border participation from venture, sovereign and corporate funds underscores a continuing wave of deep-pocketed capital flowing into "AI bio" startups. Companies attempting to move from protein-structure prediction to clinically relevant therapeutic programs typically face long pre-clinical validation cycles, high experimental costs, and regulatory gating; deep funding reduces near-term capital constraints but does not eliminate translational risk.

Sifted reports Isomorphic has signed collaboration deals with pharmaceutical companies including Eli Lilly and Novartis. Sifted further reports that Demis Hassabis told Bloomberg the company would enter clinical trials by the end of last year, and that he subsequently clarified he had been referring to pre-clinical trials, which the company has started.

Editorial analysis: Observers should monitor three measurable indicators: company disclosures of IND filings or Phase I starts; peer-reviewed or preprint publications describing predictive accuracy on binding and efficacy predictors; and announced commercial or research partnerships that include milestone or clinical-stage work. Public reporting will also clarify how much of the new capital is allocated to wet-lab scale-up, compute and regulated development versus platform R&D.

Sifted records a comment from Isomorphic president Colin Murdoch on the rationale for the spinout: "If you're designing drugs, you need chemists, pharmacologists and biologists," Murdoch said, noting those hires required a different career ladder than DeepMind provided.

Editorial analysis: The size and profile of this round materially raise the financing bar for peers in AI-driven drug discovery, and increase near-term expectations for clinical progression and partnership-led validation. That said, translating improved molecular prediction into approved therapeutics remains a multi-year, high-friction process.